Undersøgelse af blærekemoterapi i stedet for kirurgi for lavrisiko blærekræft (CALIBER)
CALIBER - En fase II randomiseret gennemførlighedsundersøgelse af kemoresektion og kirurgisk behandling ved lavrisiko ikke-muskelinvasiv blærekræft
Patients diagnosed with low risk non-muscle invasive bladder cancer (NMIBC) are at risk of frequent low grade recurrence, which usually necessitates surgical intervention under general anaesthetic. This multicentre study aims to establish the short term efficacy of chemoresection using chemotherapy within the bladder for the treatment of NMIBC.
Should the levels of complete response following chemoresection meet predefined criteria, a larger phase III trial would be developed to assess longer term disease related endpoints, with the aim of standardising management of recurrent low risk NMIBC and potentially removing the need for over a thousand patients each year to undergo surgery.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
CALIBER is a two stage phase II, multicentre, randomised controlled trial (RCT). A control group has been included to provide prospective data about surgical management and outcomes and assess feasibility of recruitment to a randomised study.
Stage 1: 80 patients will be recruited with treatment allocated 2:1 by randomisation between chemoresection and surgical management.
Stage 2: If the stop/go activity criteria at the end of stage 1 indicate that recruitment should continue, 9 additional participants will be recruited, all of whom will receive chemoresection.
Patients assigned to the chemoresection group will receive 4 once weekly intravesical instillations of 40mg Mitomycin C (MMC) as outpatients. This treatment will be delivered via catheter under local anaesthetic.
Patients assigned to the surgical management group will receive the standard surgical management in use at their hospital for treatment of recurrence which may include a single post-operative installation of 40mg MMC within 24 hours.
All participants will be followed up at 3 weeks from the start of treatment (ie at time of final MMC instillation for chemoresection group) and each will receive a cystoscopy three months from the end of treatment to assess response, in accordance with European Association of Urology (EAU) guidelines.
Subsequent cystoscopic follow up will take place 12 months after treatment if recurrence-free at 3 months and then annually.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
-
London, Det Forenede Kongerige, NW1 2BU
- University College Hospital
-
Manchester, Det Forenede Kongerige, M23 9LT
- Wythenshawe Hospital
-
Manchester, Det Forenede Kongerige, M20 2LR
- Withington Hospital
-
-
Cheshire
-
Macclesfield, Cheshire, Det Forenede Kongerige, SK10 3BL
- Macclesfield District General Hospital
-
-
Cleveland
-
Middlesbrough, Cleveland, Det Forenede Kongerige, TS4 3BW
- James Cook University Hospital
-
-
Cumbria
-
Whitehaven, Cumbria, Det Forenede Kongerige, CA28 8JG
- West Cumberland Hospital
-
-
Devon
-
Exeter, Devon, Det Forenede Kongerige, EX2 5DW
- Royal Devon and Exeter Hospital
-
Plymouth, Devon, Det Forenede Kongerige, PL6 8DH
- Derriford Hospital
-
-
Dorset
-
Bournemouth, Dorset, Det Forenede Kongerige, BH7 7DW
- Royal Bournemouth Hospital
-
Dorchester, Dorset, Det Forenede Kongerige, DT1 2JY
- Dorset County Hospital
-
-
England
-
Carlisle, England, Det Forenede Kongerige, CA2 7HY
- Cumberland Infirmary
-
-
Essex
-
Chelmsford, Essex, Det Forenede Kongerige, CM1 5ET
- Broomfield Hospital
-
Harlow, Essex, Det Forenede Kongerige, CM20 1QX
- Princess Alexandra Hospital
-
-
Gloucestershire
-
Cheltenham, Gloucestershire, Det Forenede Kongerige, GL53 7AN
- Cheltenham General Hospital
-
Gloucester, Gloucestershire, Det Forenede Kongerige, GL1 3NN
- Gloucestershire Royal Hospital
-
-
Greater Manchester
-
Manchester, Greater Manchester, Det Forenede Kongerige, OL1 2JH
- Royal Oldham Hospital
-
-
Hampshire
-
Basingstoke, Hampshire, Det Forenede Kongerige, RG24 9NA
- Basingstoke and North Hampshire Hospital
-
Southampton, Hampshire, Det Forenede Kongerige, SO16 6YD
- Southampton General Hospital
-
-
Herefordshire
-
Hereford, Herefordshire, Det Forenede Kongerige, HR1 2ER
- Hereford County Hospital
-
-
Kent
-
Dartford, Kent, Det Forenede Kongerige, DA2 8DA
- Darent Valley Hospital
-
Gillingham, Kent, Det Forenede Kongerige, ME7 5NY
- Medway Maritime Hospital
-
-
Lancashire
-
Preston, Lancashire, Det Forenede Kongerige, PR2 9HT
- Royal Preston Hospital
-
-
Leicestershire
-
Leicester, Leicestershire, Det Forenede Kongerige, LE5 4PW
- Leicester General Hospital
-
-
Middlesex
-
Harrow, Middlesex, Det Forenede Kongerige, HA1 3UJ
- Northwick Park Hospital
-
-
Oxfordshire
-
Headington, Oxfordshire, Det Forenede Kongerige, OX3 7LE
- Churchill Hospital
-
-
South Yorkshire
-
Sheffield, South Yorkshire, Det Forenede Kongerige, S10 2JF
- Royal Hallamshire Hospital
-
-
Suffolk
-
Ipswich, Suffolk, Det Forenede Kongerige, IP4 5PD
- Ipswich Hospital
-
-
Surrey
-
Croydon, Surrey, Det Forenede Kongerige, CR7 7YE
- Croydon University Hospital
-
Guildford, Surrey, Det Forenede Kongerige, GU2 7XX
- Royal Surrey County Hospital
-
-
Tyne and Wear
-
Newcastle upon Tyne, Tyne and Wear, Det Forenede Kongerige, NE7 7DN
- Freeman Hospital
-
-
West Midlands
-
Wolverhampton, West Midlands, Det Forenede Kongerige, WV10 0QP
- New Cross Hospital
-
-
West Sussex
-
Chichester, West Sussex, Det Forenede Kongerige, PO19 6SE
- St Richard's Hospital
-
Worthing, West Sussex, Det Forenede Kongerige, BN11 2DH
- Worthing Hospital
-
-
West Yorkshire
-
Wakefield, West Yorkshire, Det Forenede Kongerige, WF1 4DG
- Pinderfields General Hospital
-
-
Worcestershire
-
Kidderminster, Worcestershire, Det Forenede Kongerige, DY11 6RJ
- Kidderminster Hospital
-
Redditch, Worcestershire, Det Forenede Kongerige, B98 7UB
- Alexandra Hospital
-
Worcester, Worcestershire, Det Forenede Kongerige, WR5 1DD
- Worcester Royal Hospital
-
-
Yorkshire
-
Leeds, Yorkshire, Det Forenede Kongerige, LS9 7TF
- St James's University Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Written informed consent
- NMIBC recurrence following original diagnosis of low risk NMIBC (defined as Ta G1 or Ta G2 (Ta low grade) with a risk of recurrence score of ≤6 using EORTC risk tables
- Histologically confirmed Transitional-cell carcinoma (TCC) at original diagnosis
- Aged 16 or over
- Satisfactory pre-treatment haematology values and serum creatinine < 1.5 x Upper Limit of Normal (ULN)
- Negative pregnancy test for women of child-bearing potential
Exclusion Criteria:
- Any history of: grade 3/high grade or ≥T1 transitional cell carcinoma, concomitant carcinoma in situ, more than 7 tumours at one diagnosis or more than 1 recurrence per year since initial diagnosis or in the past five years, whichever is shorter
- Any history of histologically confirmed non-TCC bladder cancer
- Trial entry recurrence identified within 11.5 months of the date of the original diagnosis
- Any prior treatment of the trial entry recurrence (including biopsy)
- Previous MMC chemotherapy other than a single instillation at diagnostic surgery
- Known allergy to MMC
- Carcinoma involving the prostatic urethra or upper urinary tract (participants should have had imaging of the upper urinary tract within 2 years prior to randomisation)
- Known or suspected reduced bladder capacity (<100ml)
- Significant bleeding disorder
- Female patients who are breast-feeding or are of childbearing potential and unwilling or unable to use adequate non-hormonal contraception. Male patients should also use contraception if sexually active.
- Active or intractable urinary tract infection
- Urethral stricture or anything impeding the insertion of a catheter
- Large narrow neck diverticula
- Significant urinary incontinence
- Any other conditions that in the Principal Investigator's opinion would contraindicate protocol treatment
- Unable or unwilling to comply with study procedures or follow up schedule
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Chemoresection
4 once weekly outpatient intravesical instillations 40mg Mitomycin C |
Patients assigned to the chemoresection group will receive 4 once weekly intravesical instillations of 40mg MMC as outpatients.
Andre navne:
|
|
Andet: Surgical Management
Surgical management according to local practice |
Patients in this group should be treated according to local practice. Surgical interventions may include transurethral resection (TUR) or ablation. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Complete response rate with chemoresection
Tidsramme: 3 months
|
Defined as an absence of any tumour following chemoresection and will be assessed visually at 3 month check cystoscopy by patients' urologists. A biopsy of the tumour bed would take place to confirm visual assessment of complete response. |
3 months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Treatment compliance in chemoresection group
Tidsramme: Duration of treatment (3 weeks)
|
Patients who receive 4 MMC instillations with no more than 14 days between each instillation will be described as fully compliant. |
Duration of treatment (3 weeks)
|
|
Salvage surgery rates
Tidsramme: 3 years
|
Assessing trans-urethral resection and biopsy rates following initial treatment in both treatment groups |
3 years
|
|
Progression-free survival
Tidsramme: 3 years
|
Defined as time from randomisation to the first of muscle invasive bladder recurrence, recurrence in the pelvic nodes, distant metastatic recurrence or death from any cause. |
3 years
|
|
Toxicity (NCI Common Toxicity Criteria for Adverse Effects (CTCAE) V4 and Clavien Dindo grade (in surgical group))
Tidsramme: up to 12 months
|
Measuring side effects of both treatments using clinician reported toxicity scales |
up to 12 months
|
|
European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) and Superficial Bladder Cancer (BLS24) questionnaire
Tidsramme: up to 12 months
|
Assessing side effects and impact of both treatments on patient reported quality of life. |
up to 12 months
|
|
Health service utilisation
Tidsramme: up to 12 months
|
Assessed using prospective data collection of health resource usage. |
up to 12 months
|
|
Recurrence free interval
Tidsramme: up to 12 months
|
Time from end of treatment to first relapse, in patients confirmed recurrence free at 3 months |
up to 12 months
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Efterforskere
Efterforskere
- Ledende efterforsker: Hugh Mostafid, Royal Surrey County Hospital NHS Foundation Trust
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Anslået)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Urogenitale neoplasmer
- Neoplasmer efter sted
- Neoplasmer
- Mandlige urogenitale sygdomme
- Urologiske sygdomme
- Urogenitale sygdomme hos kvinder
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Urologiske neoplasmer
- Urinblæresygdomme
- Urinblære neoplasmer
- Organiske kemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ring
- Indoler
- Quinones
- Aziriner
- Mitomycins
- Indolequinones
- Mitomycin
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- ICR-CTSU/2013/10041
- 2013-005095-18 (EudraCT nummer)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .